Caterina Bucca, MD; Andrea Marsico, MD; Erika Panaro, MD; Patrizia Bigo, MD; Luisa Brussino, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Bucca C., Marsico A., Panaro E., Bigo P., Brussino L.; Statins and Nasal Polyps. Ann Intern Med. 2005;142:310-311. doi: 10.7326/0003-4819-142-4-200502150-00024
Download citation file:
Published: Ann Intern Med. 2005;142(4):310-311.
TO THE EDITOR:
Background: Chemotaxis of eosinophils is the crucial event in the development of nasal polyposis related to chronic hyperplastic eosinophilic sinusitis (1, 2). Several statins, including atorvastatin, inhibit T-helper 1 differentiation and induce T-helper 2 polarization and production of T-helper 2 cytokines, such as interleukin (IL)-5, that promote the activation and chemotaxis of eosinophils.
Methods and Findings: A 57-year-old woman with nonallergic rhinosinusitis (low serum levels of total and specific IgE, negative results on skin prick tests, and neutrophils and Staphylococcus aureus in nasal lavage), asthma, and no aspirin sensitivity presented in May 2002 for recent onset of rhinosinusitis associated with asthma attacks. She had no systemic disease. After a 2-week course of amoxicillin–clavulanate and long-term treatment with intranasal and inhaled corticosteroids plus inhaled long-acting β2-agonist, the patient's condition nearly normalized.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only